Shares of Cipla hit over 4-month high on USFDA nod for generic HIV drug. The company shares climbed as much as 3.4 per cent to Rs 622.7, highest since February 14. The stock posted biggest intraday percentage gain since June 15.
The company had said in a statement on Tuesday that it has received approval from the US health regulator to market Efavirenz tablets, used to treat HIV-1 infections in adults.
The Mumbai-based firm has received final nod from the United States Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Efavirenz tablets in 600mg strength, it said.
Cipla stock had fallen 1 per cent this year up to Tuesday's close.